A Phase 1/2 interventional study of Pentoxifylline in Cognitive Impairment, sponsored by The First Hospital of Hebei Medical University. Recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-03.
Sponsored by The First Hospital of Hebei Medical University · Phase 1/2, Interventional, and Treatment
Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function. The patients with cognitive impairment and non-dementia PSCIND after ischemic stroke were randomly divided into two groups. In addition to the basic drugs of ischemic stroke, the patients were given pentothemine sustained release tablets and blank control respectively to observe the effects of pentothemine on cognitive function and neuronal electrical signals in the patients with ischemic PSCIND. It is expected to explore the possible internal biological mechanism by using transcranial Doppler, oxygen-dependent functional magnetic resonance imaging and craniocerebral magnetic resonance pop analysis. Finally, statistical correlation analysis was used to elucidate the specific mechanism of pentoxifylline in improving cognitive function of non-dementia patients with cognitive impairment after ischemic stroke.
Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function.
2,595 studies on the registry are indexed under Ischemic Stroke; 932 are open to participants now.
This study's planned enrollment of 200 is above the median of 120 across 1,754 interventional studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →The First Hospital of Hebei Medical University is the lead sponsor of 37 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Pentoxifylline
Drug: Pentoxifylline
No intervention
Take pentoxifylline 0.4 g twice daily
Also known as: CSPC Pharmaceutical Group
Pentoxifylline can improve cognitive impairment after ischemic stroke
The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment.If the score is less than 26 points, it is considered to have cognitive impairment.Patient scores get higher after 3 months, we think pentoxifylline can improve cognitive impairment after ischemic stroke.
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Hospital of Hebei Medical University